NCT00999466

The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen

A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total. The first part will investigate the tolerability and safety of AZD8848 while the second part will investigate both the therapeutic effect of AZD8848 and how well patients tolerate the drug.

Conditions

• Allergic Asthma

Interventions

Type	Name	Description
DRUG	AZD8848	Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
DRUG	Placebo	Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-02-01
• Completion: 2011-12-01
• First posted: 2009-10-21
• Last updated: 2016-02-26
• Results posted: 2016-01-26

Locations

2 sites across 1 country: United Kingdom